Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: Polymorphisms, structure, and function of complement receptor 1

Jenny U. Johansson, William D. Brubaker, Harold Javitz, Andrew W. Bergen, Denise Nishita, Abhishek Trigunaite, Andrés Crane, Justine Ceballos, Diego Mastroeni, Andrea J. Tenner, Marwan Sabbagh, Joseph Rogers

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Genome-wide association studies consistently show that single nucleotide polymorphisms (SNPs) in the complement receptor 1 (CR1) gene modestly but significantly alter Alzheimer's disease (AD) risk. Follow-up research has assumed that CR1 is expressed in the human brain despite a paucity of evidence for its function there. Alternatively, erythrocytes contain >80% of the body's CR1, where, in primates, it is known to bind circulating pathogens. Methods: Multidisciplinary methods were employed. Results: Conventional Western blots and quantitative polymerase chain reaction failed to detect CR1 in the human brain. Brain immunohistochemistry revealed only vascular CR1. By contrast, erythrocyte CR1 immunoreactivity was readily observed and was significantly deficient in AD, as was CR1-mediated erythrocyte capture of circulating amyloid β peptide. CR1 SNPs associated with decreased erythrocyte CR1 increased AD risk, whereas a CR1 SNP associated with increased erythrocyte CR1 decreased AD risk. Discussion: SNP effects on erythrocyte CR1 likely underlie the association of CR1 polymorphisms with AD risk.

Original languageEnglish (US)
JournalAlzheimer's and Dementia
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Complement C1
Complement Receptors
Amyloid
Alzheimer Disease
Peptides
Erythrocytes
Single Nucleotide Polymorphism
Brain
Genome-Wide Association Study
Primates

Keywords

  • Amyloid β peptide
  • Clearance
  • Complement C3b/C4b receptor 1
  • Complement receptor 1
  • CR1
  • Erythrocyte
  • Immune adherence
  • Red blood cell
  • Single nucleotide polymorphism

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

Peripheral complement interactions with amyloid β peptide in Alzheimer's disease : Polymorphisms, structure, and function of complement receptor 1. / Johansson, Jenny U.; Brubaker, William D.; Javitz, Harold; Bergen, Andrew W.; Nishita, Denise; Trigunaite, Abhishek; Crane, Andrés; Ceballos, Justine; Mastroeni, Diego; Tenner, Andrea J.; Sabbagh, Marwan; Rogers, Joseph.

In: Alzheimer's and Dementia, 01.01.2018.

Research output: Contribution to journalArticle

Johansson, Jenny U. ; Brubaker, William D. ; Javitz, Harold ; Bergen, Andrew W. ; Nishita, Denise ; Trigunaite, Abhishek ; Crane, Andrés ; Ceballos, Justine ; Mastroeni, Diego ; Tenner, Andrea J. ; Sabbagh, Marwan ; Rogers, Joseph. / Peripheral complement interactions with amyloid β peptide in Alzheimer's disease : Polymorphisms, structure, and function of complement receptor 1. In: Alzheimer's and Dementia. 2018.
@article{ef8baef482e444e595dcd3ff81f53a19,
title = "Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: Polymorphisms, structure, and function of complement receptor 1",
abstract = "Introduction: Genome-wide association studies consistently show that single nucleotide polymorphisms (SNPs) in the complement receptor 1 (CR1) gene modestly but significantly alter Alzheimer's disease (AD) risk. Follow-up research has assumed that CR1 is expressed in the human brain despite a paucity of evidence for its function there. Alternatively, erythrocytes contain >80{\%} of the body's CR1, where, in primates, it is known to bind circulating pathogens. Methods: Multidisciplinary methods were employed. Results: Conventional Western blots and quantitative polymerase chain reaction failed to detect CR1 in the human brain. Brain immunohistochemistry revealed only vascular CR1. By contrast, erythrocyte CR1 immunoreactivity was readily observed and was significantly deficient in AD, as was CR1-mediated erythrocyte capture of circulating amyloid β peptide. CR1 SNPs associated with decreased erythrocyte CR1 increased AD risk, whereas a CR1 SNP associated with increased erythrocyte CR1 decreased AD risk. Discussion: SNP effects on erythrocyte CR1 likely underlie the association of CR1 polymorphisms with AD risk.",
keywords = "Amyloid β peptide, Clearance, Complement C3b/C4b receptor 1, Complement receptor 1, CR1, Erythrocyte, Immune adherence, Red blood cell, Single nucleotide polymorphism",
author = "Johansson, {Jenny U.} and Brubaker, {William D.} and Harold Javitz and Bergen, {Andrew W.} and Denise Nishita and Abhishek Trigunaite and Andr{\'e}s Crane and Justine Ceballos and Diego Mastroeni and Tenner, {Andrea J.} and Marwan Sabbagh and Joseph Rogers",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jalz.2018.04.003",
language = "English (US)",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Peripheral complement interactions with amyloid β peptide in Alzheimer's disease

T2 - Polymorphisms, structure, and function of complement receptor 1

AU - Johansson, Jenny U.

AU - Brubaker, William D.

AU - Javitz, Harold

AU - Bergen, Andrew W.

AU - Nishita, Denise

AU - Trigunaite, Abhishek

AU - Crane, Andrés

AU - Ceballos, Justine

AU - Mastroeni, Diego

AU - Tenner, Andrea J.

AU - Sabbagh, Marwan

AU - Rogers, Joseph

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Genome-wide association studies consistently show that single nucleotide polymorphisms (SNPs) in the complement receptor 1 (CR1) gene modestly but significantly alter Alzheimer's disease (AD) risk. Follow-up research has assumed that CR1 is expressed in the human brain despite a paucity of evidence for its function there. Alternatively, erythrocytes contain >80% of the body's CR1, where, in primates, it is known to bind circulating pathogens. Methods: Multidisciplinary methods were employed. Results: Conventional Western blots and quantitative polymerase chain reaction failed to detect CR1 in the human brain. Brain immunohistochemistry revealed only vascular CR1. By contrast, erythrocyte CR1 immunoreactivity was readily observed and was significantly deficient in AD, as was CR1-mediated erythrocyte capture of circulating amyloid β peptide. CR1 SNPs associated with decreased erythrocyte CR1 increased AD risk, whereas a CR1 SNP associated with increased erythrocyte CR1 decreased AD risk. Discussion: SNP effects on erythrocyte CR1 likely underlie the association of CR1 polymorphisms with AD risk.

AB - Introduction: Genome-wide association studies consistently show that single nucleotide polymorphisms (SNPs) in the complement receptor 1 (CR1) gene modestly but significantly alter Alzheimer's disease (AD) risk. Follow-up research has assumed that CR1 is expressed in the human brain despite a paucity of evidence for its function there. Alternatively, erythrocytes contain >80% of the body's CR1, where, in primates, it is known to bind circulating pathogens. Methods: Multidisciplinary methods were employed. Results: Conventional Western blots and quantitative polymerase chain reaction failed to detect CR1 in the human brain. Brain immunohistochemistry revealed only vascular CR1. By contrast, erythrocyte CR1 immunoreactivity was readily observed and was significantly deficient in AD, as was CR1-mediated erythrocyte capture of circulating amyloid β peptide. CR1 SNPs associated with decreased erythrocyte CR1 increased AD risk, whereas a CR1 SNP associated with increased erythrocyte CR1 decreased AD risk. Discussion: SNP effects on erythrocyte CR1 likely underlie the association of CR1 polymorphisms with AD risk.

KW - Amyloid β peptide

KW - Clearance

KW - Complement C3b/C4b receptor 1

KW - Complement receptor 1

KW - CR1

KW - Erythrocyte

KW - Immune adherence

KW - Red blood cell

KW - Single nucleotide polymorphism

UR - http://www.scopus.com/inward/record.url?scp=85049838666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049838666&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2018.04.003

DO - 10.1016/j.jalz.2018.04.003

M3 - Article

C2 - 29792870

AN - SCOPUS:85049838666

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

ER -